

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 20 June 2001 (20.06.01)	
International application No. PCT/US00/40091	Applicant's or agent's file reference 1321.2.28
International filing date (day/month/year) 01 June 2000 (01.06.00)	Priority date (day/month/year) 01 June 1999 (01.06.99)
Applicant BESSEREAU, Jean-Louis et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 22 December 2000 (22.12.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Sean Taylor Telephone No.: (41-22) 338.83.38
---	---

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/40091

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C12N 15/09, 15/70, 15/63, 15/00

US CL : 435/6, 320.1, 455, 473; 800/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 320.1, 455, 473; 800/21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST, medline, EMBASE, SciSearch.**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,051,430 A (PLASTERK, et al.) 18 April 2000 (18.04.2000), columns 1-4.	1-6 and 9-14
X	FUKUSHIGE, T. et al. Modulation of Gene Expression in the Embryonic Digestive Tract of <i>C. elegans</i> . Developmental Biology. 1996, Vol. 178, pages 276-288, especially pages 276 and 277.	1-56
X	VAN LUENEN, H. et al. The Mechanism of Transposition of Tc3 in <i>C. elegans</i> . Cell. 21 October 1994, Vol. 79, pages 293-301, entire document.	1-56
X	VOS, J. et al. Transposase is the Only Nematode Protein Required for in vitro Transposition of Tc1. Genes & Development. 1996, Vol. 10, pages 755-761, especially results.	1-56
Y	PLASTERK, R. Reverse Genetics of <i>Caenorhabditis elegans</i> . BioEssays. September 1992, Vol. 14, No. 9, pages 629-633, entire document.	1-56
X	PLASTERK, R. et al. Targeted Alterations of the <i>Caenorhabditis elegans</i> Genome by Transgene Instructed DNA Double Strand Break Repair Following Tc1 Excision. The EMBO Journal. 1992, Vol. 11, No. 1, pages 287-290, entire document.	1-56
X	GRUIDL, M. et al. Multiple Potential Germ-line Helicases are Components of the Germ-line-specific P Granules of <i>Caenorhabditis elegans</i> . Proc. Natl. Acad. Sci., USA. November, 1996, Vol. 93, pages 13837-13842, entire document.	7,8 and 15-17

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

28 July 2000 (28.07.2000)

Date of mailing of the international search report

23 AUG 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

David Nikodem


Telephone No. (703) 308-0196

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 1321.2.28	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/40091	International filing date (day/month/year) 01 June 2000 (01.06.2000)	Priority date (day/month/year) 01 June 1999 (01.06.1999)
International Patent Classification (IPC) or national classification and IPC IPC(7): C12Q 1/68; C12N 15/09, 15.70, 15/63, 15/00 and US Cl.: 435/6, 320.1, 455, 473; 800/21		
Applicant UNIVERSITY OF UTAH RESEARCH FOUNDATION		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>5</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>0</u> sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of report with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application 		
Date of submission of the demand 22 December 2000	Date of completion of this report	
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer James Martinell Telephone No. (703) 308-0196	

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/40091

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-34 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the claims:
pages 35-38 as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the drawings:
pages 1-9 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☐ the sequence listing part of the description:
pages NONE as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages NONE
- ☐ the claims, Nos. NONE
- ☐ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/40091

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
☒ claims Nos. 26

because:

- ☐ the said international application, or the said claim Nos. _____ relate to the following subject matter which does not require international preliminary examination (*specify*):

- ☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 26 are so unclear that no meaningful opinion could be formed (*specify*):

Claim 26 depends from itself (see PCT Rule 6.4(a)).

- ☐ the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.
☐ no international search report has been established for said claims Nos. _____

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
☐ the computer readable form has not been furnished or does not comply with the standard.

WRITTEN OPINION

International application No.
PCT/US00/40091

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims <u>Please See Continuation Sheet</u>	YES
	Claims <u>Please See Continuation Sheet</u>	NO
Inventive Step (IS)	Claims <u>Please See Continuation Sheet</u>	YES
	Claims <u>Please See Continuation Sheet</u>	NO
Industrial Applicability (IA)	Claims <u>Please See Continuation Sheet</u>	YES
	Claims <u>Please See Continuation Sheet</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1, 2, 5, 6, 9, 10, 13, 14, 20, 21, 25, 28, 29, and 33 lack novelty under PCT Article 33(2) as being anticipated by Fukushima et al (Dev. Biol. 178: 276 (1996)). Fukushima et al teaches the production of transgenic *C. elegans* using Tc1 and thus is embraced by the claims.

Claims 1-3, 5, 6, 9-11, 13, 14, 20-25, and 33 lack novelty under PCT Article 33(2) as being anticipated by van Luenen et al (Cell 79: 293 (1994)). Van Luenen et al teaches the production of transgenic *C. elegans* using Tc3 transposase and a heat shock promoter and thus is embraced by the claims.

Claims 1-3, 5, 6, 9-11, 13, 14, 20, 21, 25, 28, 29, and 33 lack novelty under PCT Article 33(2) as being anticipated by Vos et al (Genes & Development 10: 755 (1996)). Voss et al teaches the production of transgenic *C. elegans* using Tc1 transposase and a heat shock promoter and thus is embraced by the claims.

Claims 4, 7, 8, 12, 15-19, 27, 30-32, and 34-56 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the transgenic constructs or methods of the claims.

----- NEW CITATIONS -----

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US00/40091

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

V.1. Reasoned Statements:

The opinion as to Novelty was positive (Yes) with respect to claims 4, 7, 8, 12, 15-19, 27, 30-32, and 34-56

The opinion as to Novelty was negative (No) with respect to claims 1-3, 5, 6, 9-11, 13, 14, 20-25, 28, 29, and 33

The opinion as to Inventive Step was positive (Yes) with respect to claims 4, 7, 8, 12, 15-19, 27, 30-32, and 34-56

The opinion as to Inventive Step was negative (NO) with respect to claims 1-3, 5, 6, 9-11, 13, 14, 20-25, 28, 29, and 33

The opinion as to Industrial Applicability was positive (YES) with respect to claims 1-25 and 27-56

The opinion as to Industrial Applicability was negative (NO) with respect to claims NONE

P, ENT COOPERATION TREA.

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

MADSON, Craig, J.
Madson & Metcalf
Gateway Tower West
Suite 900
15 West South Temple
Salt Lake City, UT 84101
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 05 octobre 2001 (05.10.01)	
Applicant's or agent's file reference 1321.2.28	IMPORTANT NOTIFICATION
International application No. PCT/US00/40091	International filing date (day/month/year) 01 juin 2000 (01.06.00)

1. The following indications appeared on record concerning: <input checked="" type="checkbox"/> the applicant <input type="checkbox"/> the inventor <input type="checkbox"/> the agent <input type="checkbox"/> the common representative		
Name and Address SEE OBSERVATIONS BELOW.	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: <input checked="" type="checkbox"/> the person <input type="checkbox"/> the name <input type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence		
Name and Address INSERM 101, rue de Tolbiac F-75654 Paris Cedex 13 France	State of Nationality FR	State of Residence FR
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary: The applicant identified in Box 2 has been added to the record as applicant for the purposes of all designated States except the United States of America.		
4. A copy of this notification has been sent to: <input checked="" type="checkbox"/> the receiving Office <input type="checkbox"/> the designated Offices concerned <input type="checkbox"/> the International Searching Authority <input checked="" type="checkbox"/> the elected Offices concerned <input checked="" type="checkbox"/> the International Preliminary Examining Authority <input type="checkbox"/> other:		

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Diana NISSEN
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/073510 A1

(51) International Patent Classification⁷: C12Q 1/68,
C12N 15/09, 15/70, 15/63, 15/00

(21) International Application Number: PCT/US00/40091

(22) International Filing Date: 1 June 2000 (01.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/136,972 1 June 1999 (01.06.1999) US

(71) Applicants (for all designated States except US): UNI-
VERSITY OF UTAH RESEARCH FOUNDATION
[US/US]; Suite 110, 615 Arapen Drive, Salt Lake City,
UT 84108 (US). INSERM [FR/FR]; 101, rue de Tolbiac,
F-75654 Paris Cedex 13 (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BESSEREAU,
Jean-Louis [FR/FR]; I.N.S.E.R.M.U. 497, I.N.S.E.R.M.U.,
46, rue D'Ulm, F-75005 Paris (FR). JORGENSEN, Erik
[US/US]; 1127 East 400 South, Salt Lake City, UT 84102
(US).

(74) Agent: MADSON, Craig, J.; Madson & Metcalf, Gate-
way Tower West, Suite 900, 15 West South Temple, Salt
Lake City, UT 84101 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(48) Date of publication of this corrected version:
8 August 2002

(15) Information about Correction:
see PCT Gazette No. 32/2002 of 8 August 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 00/073510 A1

(54) Title: METHOD OF TRANSPOSON-MEDIATED MUTAGENESIS IN THE NEMATODE *CAENORHABDITIS ELEGANS*

(57) Abstract: The present invention provides methods for generating and identifying mutations in *C. elegans*. Disclosed herein are methods for introducing DNA into the *C. elegans* germline, methods for expressing DNA in the *C. elegans* germline, and methods for generating *C. elegans* mutants by using controlled mobilization of endogenous and heterologous transposons. Also disclosed are a transgene construct for expression in *C. elegans* and methods for inserting single copy DNA sequences into the *C. elegans* germline, and engineering mutations into the *C. elegans* genome.

METHOD OF TRANSPOSON-MEDIATED MUTAGENESIS IN THE NEMATODE *CAENORHABDITIS ELEGANS*

1. FIELD OF THE INVENTION

5 The present invention relates to methods for generating and identifying mutations in the genome of the nematode *Caenorhabditis elegans* (hereinafter "*C. elegans*"). More specifically, the present invention relates to a transgene construct for expression in *C. elegans*, and to methods for regulating mobilization of heterologous or endogenous transposons in the *C. elegans* genome, inserting a heterologous DNA sequence into *C. elegans* germline DNA, and engineering mutations into the *C. elegans* genome.

2. TECHNICAL BACKGROUND

10 The use of model genetic systems had its beginnings in the earliest days of the science of genetics and, as a result of the tremendous value of such systems in understanding genetic phenomena, continues in the present. Researchers often use in their work organisms which have short life spans, limited space requirements, and relatively small genomes. Specifically, certain species of worms, fruit flies, and yeast cells are common subjects of research. Using such organisms, researchers may learn the function of the various genes found within the DNA of the organisms. One commonly used method is to generate mutations in the genome of an organism, followed by selection or screening for those mutations which confer a specific property or characteristic to the organism. These mutational studies suggest probable functions for the genes in which mutations occur. Mutations often occur when a gene is changed in such a way that the product of the gene is altered or nonfunctional.

25 A common method for generating mutations uses transposable elements. Transposable elements are segments of DNA which have the ability to "hop"—that is, to be excised from their initial position in the DNA and move to a new location. In doing this, a transposable element, also known as a transposon, may insert into some portion of a gene, thus disrupting or even changing the function of the gene. Further, additional mutations may be created by remobilizing the transposon. Since this remobilization often occurs imperfectly, changes are created in the DNA sequence, leaving the final sequence different from the original sequence. See J.D. Watson, J. Witkowski, M. Gilman, and M. Zoller, *Recombinant DNA* 175-190, 439-440 2d. ed. (1996).

The P element, a transposable element found in the genes of fruit flies, *see, e.g.*, A. C. Spradling, G. M. Rubin, *Science* **218**, 341 (1982); J.D. Watson, J. Witkowski, M. Gilman, and M. Zoller, *Recombinant DNA* 175, 177 2d. ed. (1996). has been an enormously useful tool in *Drosophila* genetic analysis for two reasons. First, these transposons have been used for insertional mutagenesis. Mutagenic insertions constitute molecular tags that are used to rapidly clone the mutated gene. L. Cooley, R. Kelley, A. Spradling, *Science* **239**, 1121 (1988). Particularly helpful in such studies is the presence of strains that lack any copies of the transposon. Second, P elements are used to introduce single copies of foreign sequences into the host genome. This feature is particularly useful for the rapid identification of gene expression patterns by using enhancer traps. H. J. Bellen, et al., *Genes Dev.* **3**, 1288 (1989). The availability of such techniques would be particularly advantageous in studies of the genome of the nematode *C. elegans*.

C. elegans is a model system in which genetics can be used to identify genes and biological pathways which are conserved between nematodes and vertebrates, and which thus constitute potential targets for the treatment of various diseases. *C. elegans* is particularly advantageous for genetic studies because it is easily propagated and because the genetic and physical maps of its genome are well-characterized. W. B. Wood, *Introduction to C. elegans Biology* (1988). The characterization of gene structure in *C. elegans* has become routine, largely through the efforts of the *C. elegans* genome project. The workers involved in this effort have cloned the entire genome into cosmid or YAC vectors and have completed the genomic sequence. *C. elegans* Sequencing Consortium, *Science* **282**:2012-2018 (1998); A. Coulson et al., *Proc Natl Acad Sci USA* **83**:7821-7825 (1986); A. Coulson et al., *Bioessays* **13**:413-417 (1991); R. Wilson et al., *Nature* **368**:32-38 (1994).

Standard mutagenesis in *C. elegans* employs chemical mutagens. After generation of a mutant, identification of the gene requires time-consuming genetic mapping followed by single gene rescue. Alternatively, transposon-based mutagenesis has been attempted using mutant backgrounds like *mut-2*, but efficiency of transposition is low and not specific for a defined transposon class. Further, since the genomes of all *C. elegans* strains contain transposons, it is very difficult to identify relevant insertions. Thus, utility of native transposons for regulated transposition in *C. elegans* is limited. First, all strains contain multiple copies of these transposons and thus new insertions do not provide

unique tags. Second, mutator strains tend to activate the transposition of several classes of transposons, so that the type of transposon associated with a particular mutation is not known. Third, transposition is not regulated and the transposon tag can be lost by excision in subsequent generations. Fourth, attempts to regulate transposase expression have failed because expression of transgenes in the germline of *C. elegans* is very difficult. Although one could theoretically regulate the transposition of a specific element by expressing the transposase under the control of a germline-specific promoter, transgenic arrays are typically silenced in the germline. W. G. Kelly, S. Xu, M. K. Montgomery, A. Fire, *Genetics* 146, 227 (1997)

Another problem in this field is the difficulty of expressing DNA in the *C. elegans* germline. Current methods, *see, e.g.*, W. G. Kelly et al., *Genetics* 146:227-238 (1997), are not adequate. First, current methods for expressing foreign DNA in the *C. elegans* germline do not work for all genes. Second, expression of genes introduced using these methods declines over time.

Finally, introduction of single copy DNA is not possible using existing technology.

From the foregoing, it will be appreciated that it would be a significant advancement in the art to provide methods that allow regulated expression of foreign DNA in the *C. elegans* germline. It would be a further advancement to provide methods that allow germline expression of a transgene in *C. elegans*. It would be a further advancement in the art to provide regulated expression of such a transgene in the germline, as by regulation using a heat-shock promoter. It would be a further advancement to provide methods of regulating the transposition of either endogenous or heterologous transposons in *C. elegans*. Further, it would be an advancement to provide transgene constructs to facilitate germline expression of transgenes and regulated transposition of homologous and heterologous transposons. Such compositions of matter and methods are disclosed herein.

3. BRIEF SUMMARY OF THE INVENTION

The present invention relates to improved methods for generating and identifying mutations in *C. elegans*, and includes methods for introducing heterologous DNA into the *C. elegans* germline and causing its expression. In certain embodiments, a method of the

present invention comprises the steps of inserting a transgene construct into the *C. elegans*, wherein the construct comprises a heterologous gene operably linked to a promoter and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline; and expressing the heterologous gene. In certain embodiments, this method further comprises the removal of all bacterial plasmid sequences and repeated sequences from the DNA to be introduced. In certain preferred embodiments, a promoter that is active in the *C. elegans* germline drives expression of the transgene. In certain especially preferred embodiments, the promoter is an inducible promoter.

The present invention further relates to a transgene construct for expression in *C. elegans* which comprises a heterologous gene operably linked to a promoter and a 3' untranslated region of a gene expressed in the *C. elegans* genome. In certain embodiments, the transgene construct further comprises a promoter that is active in the germline of *C. elegans* or a promoter that is inducible.

The present invention further relates to methods for generating and identifying mutations in *C. elegans*. In one embodiment, a method of the present invention comprises the introduction and expression of a transposase gene to mobilize either endogenous or heterologous transposons. In certain preferred embodiments, the transposons are endogenous Tc3 transposons.

In certain other embodiments, the transposons are heterologous transposons, such as the *Drosophila* mariner element. Controlled mobilization of heterologous transposons allows the generation of mutations, which are tagged by the insertion of the transposon. PCR-based techniques permit rapid identification of the transposon insertion that caused the mutation.

The present invention further relates to methods for introducing single copy DNA sequences into *C. elegans*. In certain preferred embodiments, a method of the present invention comprises introducing a transposon comprising a heterologous DNA sequence into a *C. elegans*, introducing a transgene construct comprising a transposase gene operably linked to a promoter and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline, and expressing the transposase such that the transposase integrates into a *C. elegans* chromosome as a single copy. The transposon may be engineered to introduce a DNA sequence, such as one that codes for a reporter gene such as, for example, a green fluorescent protein. The introduced DNA sequence may also

contain FRT/FLP or CRE/LOX recombination sites. Alternatively, the introduced DNA sequence may contain polyadenylation sites or transcriptional terminators.

These and other features and advantages of the present invention will become more fully apparent from the following detailed description.

5 4. SUMMARY OF THE DRAWINGS

Figure 1 schematically depicts a method for mutagenesis by controlled heterologous transposition.

Figure 2 depicts the structure of the pJL44 *Mos1* transposase expression vector.

Figure 3 schematically depicts a method for identifying sequences flanking the
10 *Mos 1* insertion site using inverse PCR.

Figure 4 depicts the sequence (SEQ ID NO.: 23) of an inverse PCR product. Nucleotides in capital letters are from the *Mos1* transposon. The *C. elegans* flanking genomic region is in lower case. It matches the Y47C4.A sequence from chromosome X available at the Sanger Centre. See the Sanger Centre web site at
15 http://www.sanger.ac.uk/Projects/C_elegans/.

Figure 5 depicts the mobilization of *Mos1* in *C. elegans* somatic cells. (A) Engineering of the *Mos* transposase encoding sequence. Restriction sites were generated at the 5' and 3' ends of the coding sequence (new sequence is indicated under the original sequence). The endogenous polyadenylation signal (boxed) was disrupted and an
20 artificial intron was introduced in the coding sequence in order to improve transposase expression. See A. Fire, S. W. Harrison, D. Dixon, *Gene* 93, 189 (1990). (B) Localization of *Mos1* insertions in *unc-49* and *gpa-2* genes after induction of *Mos* transposase expression in somatic cells. Open triangles: insertion sites; black rectangles: coding exons; white rectangle: non coding exonic sequence. Arrows: genomic primers used to
25 amplify the insertions. (C) Sequence comparison of 22 insertion sites. Insertion sites are oriented relative to the 5' end of the *Mos1* transposon. Sequences that flank *Mos1* at the right end were identified by PCR. DNA purification and PCR were performed as described in H. G. van Luenen, S. D. Colloms, R. H. Plasterk, *Embo J.* 12, 2513 (1993). The primers in *Mos1* were oJL88 (5'-CGCATGCGGCTTACTCAC (SEQ ID NO: 4))
30 first PCR; and oJL89 (5'-GGCCCCATCCGATTACCACCTA (SEQ ID NO: 5)) second PCR. Primers in *unc-49* were oJL19 (5'-GCGAAACGCATACCAACTGTA (SEQ ID

NO: 6)) first PCR; and oJL20 (5'-TTCATGCCGAAAAGCAGGCGT (SEQ ID NO: 7)) second PCR. Primers in *gpa-2* were the same as described in H. G. van Luenen, S. D. Colloms, R. H. Plasterk, *Embo J.* 12, 2513 (1993). PCR products were gel-purified and sequenced using oJL89 (SEQ ID NO: 5) as a primer. (positive positions on the graph), sequences that flank the left end of *Mos1* were deduced from *unc-49* and *gpa-2* sequences
 5 (negative positions on the graph).

Figure 6 depicts germline mobilization of *Mos1*. (A) *Mos* transposase was expressed from an extrachromosomal array using either a *glh-2* or a heat-shock promoter. The *Mos1* transposon was contained in an array integrated on chromosome V (oxIs25[Mos1;rol-6(sd)]). The array containing chromosome was balanced by the dpy-
 10 11(e224) mutation. In the next generation, catastrophic excision of the transgene was observed (indicated as ΔoxIs) among the progeny. (B) Comparison of excision and insertion frequencies using *glh-2* and heat-shock (*hsp*) promoters to drive *Mos* transposase expression in the germline. New *Mos1* insertions were identified by PCR. Specifically, the presence of *Mos1* was detected through PCR by using two primers
 15 located in the transposon, oJL102 (SEQ ID NO: 1) and oJL103 (SEQ ID NO: 3). The absence of *D. mauritiana* flanking sequence was checked using oJL102 (SEQ ID NO: 1) and oJL104 (SEQ ID NO: 2) as described below. In addition, a PCR positive control was performed on each DNA sample using oligonucleotides located in the *cha-1* gene. Recombination events were recognized as Dpy worms also containing *Mos1* flanked by
 20 original *Drosophila* genomic sequences.

Figure 7 shows *Mos1* genomic insertions. (A) Southern blot probed with labelled *Mos1* DNA. Lane 1 to 8, strains in which insertions were detected by PCR; insertions derived from an extrachromosomal array and *Mos* transposase expressed under the heat-shock promoter. *Mos1* presence was assessed by PCR using two primers located in the
 25 transposon (oJL102 (SEQ ID NO: 1) and oJL103 (SEQ ID NO: 3)). The absence of *D. mauritiana* flanking sequence was checked using oJL102 (SEQ ID NO: 1) and oJL104 (SEQ ID NO: 2), while a PCR positive control was performed on each DNA sample using oligonucleotides located in the *cha-1* gene. The control lane is *lin-15*(n765) which had been used to build transgenic lines. Each lane contains 2 mg of Bgl II digested genomic
 30 DNA. The *Mos1* probe (encompassing bases 1 to 174 of the transposon) was synthesized by PCR using the pBluescribeM13+/Mos1 plasmid as a template. (B) Distribution of

Mos1 inserts on the physical map of the *C. elegans* genome. Black triangles: insertions from an extrachromosomal array. Open triangles: insertions from the integrated array oxIs25. Open circle: position of oxIs25, the integrated array of *Mos1* transposons. (C) DNA sequence of *Mos1* de novo insertions. Genomic fragments that flank the transposon left end were isolated by inverse PCR and sequenced. A primer was designed in the genomic region to the right of the insert and used with a *Mos1* specific primer to amplify and sequence the right end flanking the fragment. At insertion sites TA dinucleotides (bold) were duplicated during the process of transposon integration. Lower case: *Mos1* sequence. Upper case: genomic sequence.

Figure 8 shows a knock-in strategy wherein *Mos1* excision causes a DNA double strand break, after which a transgene containing sequences homologous to the excision region pairs with the chromosome. Finally, the mutation contained in the transgene is copied into the chromosome.

These drawings only provide information concerning typical embodiments of the invention and are not therefore to be considered limiting of its scope.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel methods for generating and identifying mutations in *C. elegans*, and includes methods for introducing a transgene into the *C. elegans* germline. The present invention also includes methods for expressing transgenes in the *C. elegans* germline. The present invention also includes a transgene construct for expression in *C. elegans* and methods for generating mutations by regulating the transposition of endogenous or heterologous transposons in *C. elegans*. The present invention also includes methods for inserting single copy DNA into a *C. elegans* genome by introducing a transgene comprising FLP Recombination Target (FRT) sites into a *C. elegans* and causing recombination. FLP is a site-specific recombinase which efficiently catalyzes recombination between FRT sites that have been placed in the genome. K. G. Golic, S. L. Lindquist, *Cell* 44, 521 (1986). When FRT sites are in the same relative orientation within a chromosome, the FLP recombinase excises the intervening DNA from the chromosome. See Golic, Kent G., Generating Mosaics By Site-Specific Recombination, *In Cellular Interactions In Development: A Practical Approach*, 1-31 (D. A. Hartley, ed., Oxford Univ. Press 1993); and Plasterk R.H., Groenen J.T., Targeted

Alterations of the *Caenorhabditis elegans* Genome by Transgene Instructed DNA Double Strand Break Repair Following Tc1 Excision, *EMBO J.*, 11:287-90 (1992). Other recombination systems, such as CRE/LOX, could also be used.

All publications, patents, and patent applications cited herein are hereby incorporated by reference. U.S. Patent Application Serial No. 60/136,972 is hereby
5 incorporated by reference in its entirety.

DEFINITIONS

The term "heterologous" is used herein to include nucleic acid sequences such as coding sequences and control sequences that are not normally joined together, and/or are not normally associated with a particular cell. Thus, a heterologous region of a construct
10 or vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with this other molecule in nature. For example, a heterologous region of a nucleic acid construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature (e.g., synthetic sequences having codons different from the native gene). Similarly, a cell transformed
15 with a construct which is not normally present in the cell would be considered heterologous for purposes of this invention. The term includes, but is not limited to, a DNA sequence from another organism.

The term "transgene" is a heterologous sequence that is introduced into an organism. The term includes both sequences that integrate into one or more chromosomal
20 locations of the organism and sequences that are maintained extrachromosomally, e.g., as episomes.

The term "regulable expression control element" includes promoters, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites, enhancers, and the like,
25 which provide for the replication, transcription, and translation of a coding sequence in a recipient cell or in a cell of an organism. The term promoter refers to a DNA sequence, that is capable of binding RNA polymerase and initiating transcription of a downstream (3' direction) sequence. Inducible promoters are promoters which are regulable. Such promoters may be regulated by, for example, temperature, small molecules, or
30 developmental stages of an organism.

Inducible promoters include heat-shock promoters, which are induced by exposure

to heat. Inducible also promoters include small molecule-regulated promoters. Other inducible promoters include promoters that are induced (or repressed) by tetracycline and its derivatives (Gossen & Bujard, *Proc. Natl. Acad. Sci. USA* 89:5547-5551 (1992)).

“Operably linked” refers to an arrangement of elements in which the components so described are configured so as to perform their usual function. Thus, control sequences
5 such as regulable expression control elements operably linked to a coding sequence are capable of affecting the expression of the coding sequence. The control sequences need not be contiguous with the coding sequence so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter
10 sequence can still be considered “operably linked” to the coding sequence.

For the purpose of describing the relative position of nucleotide sequences in a particular nucleic acid molecule throughout the instant application, such as when a particular nucleotide sequence is described as being situated “upstream,” “downstream,” “3’,” or “5’,” relative to another sequence, it is to be understood that it is the position of
15 the sequences in the “sense” or “coding” strand of a DNA molecule that is being referred to as is conventional in the art.

GENERAL METHODS

In one embodiment, a method of regulated expression of a heterologous gene in cells of the germline of *C. elegans* comprises the steps of inserting a transgene construct
20 into the *C. elegans*, wherein the construct comprises the heterologous gene operably linked to a promoter and a 3’ untranslated region of a gene that is expressed in the *C. elegans* germline; and expressing the heterologous gene. Other embodiments further comprise the use of a promoter which is inducible, such as a heat-shock promoter or a tetracycline-regulated promoter. Yet other preferred embodiments comprise the removal
25 of substantially all bacterial plasmid sequences and repeated sequences from the transgene. In certain other especially preferred embodiments, the method of the present invention comprises the addition of the 3’ untranslated region (UTR) of the *glh-2* gene, which is expressed in the *C. elegans* germline, to the 3’ end of the transgene. A promoter, such as a *glh-2* promoter, which is a germline specific promoter, may be used to drive
30 expression of the transgene.

The present invention further comprises transgene constructs for expression in *C.*

elegans which comprises a heterologous gene operably linked to a promoter and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline. In certain embodiments, the promoter is active in the cells of the germline of *C. elegans*. In other embodiments, the promoter comprises an inducible promoter such as a heat-shock promoter or a tetracycline-regulated promoter expressed in the germline. Yet other
5 embodiments comprise the removal of substantially all bacterial plasmid sequences and repeated sequences from the transgene. In certain preferred embodiments, the method of the present invention comprises the addition of a 3' untranslated region (UTR) of a *glh-2* gene, which is expressed in the *C. elegans* germline, to the 3' end of the transgene. A promoter, such as a *glh-2* promoter, may be used to drive expression of the transgene. In
10 still other embodiments, the heterologous gene codes for a transposase. In certain preferred embodiments, the heterologous gene is a TC3A transposase gene.

The present invention also includes methods for generating mutations in the genome of a *C. elegans* by using controlled mobilization of transposons. In certain embodiments, the method for generating mutations in the genome of a *C. elegans*
15 comprises the steps of introducing a transgene construct comprising a transposase gene which is operably linked to a regulable expression control element and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline into a *C. elegans*; and expressing the transposase gene. Such methods allow the generation of mutants in which the mutated genes are tagged by the insertion of the transposon. PCR-based techniques
20 permit fast identification of the transposon insertion that causes the mutation. Since the *C. elegans* genome has been entirely sequenced, sequencing of the genomic regions that flank the transposon allows immediate identification of the mutated gene.

In certain embodiments, transposons used in the method of the present invention are endogenous transposons. Several different types of endogenous transposons are
25 present in *C. elegans*, and these can be mobilized in mutator strains. See, e.g., R. H. A. Plasterk, H. G. A. M. van Luenen, in *C. elegans II*, D. L. Riddle, T. Blumenthal, B. J. Meyer, J. R. Priess, Eds. (Cold Spring Harbor Laboratory Press, New York, 1997) pp. 97-116. Mutator alleles have been useful in cloning *C. elegans* genes, particularly in early studies before the genome project reagents were widely available. In certain preferred
30 embodiments, the endogenous transposons are Tc3 transposons. In yet other embodiments, the transposase gene is a TC3A transposase gene. In still other

embodiments, the regulable expression control element is an inducible promoter, comprising in some embodiments a heat-shock promoter or a tetracycline-regulated promoter. Yet other embodiments comprise the removal of substantially all bacterial plasmid sequences and repeated sequences from the transgene construct. In certain preferred embodiments, the method of the present invention comprises the addition of the
5 3' untranslated region (UTR) of the *glh-2* gene, which is expressed in the *C. elegans* germline, to the 3' end of the transgene. In such embodiments, the regulable expression control element comprises a promoter, such as a *glh-2* promoter or a heat-shock promoter, which may be used to drive expression of the transgene.

In other embodiments, mutants may be generated by using controlled mobilization
10 of heterologous transposons. Using a heterologous transposon allows researchers to tag mutated genes with a sequence that is unique in *C. elegans* genome. These tagged mutations will allow the rapid cloning of the mutated genes. The primary advantage over the endogenous transposon scheme is that this method avoids the isolation of irrelevant insertions of the endogenous *C. elegans* transposons. A further advantage is that the
15 expression of the heterologous transposase would only mobilize the heterologous element, and thus mutations should only be due to insertions of these elements. Additionally, insertions could be stabilized by loss of the transposase-expressing construct.

In certain preferred embodiments, *Mos1*, a *mariner*-like transposon isolated from
20 *Drosophila mauritiana*, is used. M. Medhora et al., *Genetics* 128:311-318 (1991). See generally D. L. Hartl et al., *Annu. Rev. Genet.* 31:337-358 (1997). *Mos1* is a member of the *mariner/Tc1* family and was initially identified in the fruitfly *Drosophila mauritiana*. J. W. Jacobson, M. M. Medhora, D. L. Hartl, *Proc. Natl. Acad. Sci. U S A* 83, 8684 (1986). Like the other members of the *mariner/Tc1* family, *Mos1* contains a single open
25 reading frame which encodes the transposase. The transposase binds to and cleaves at the inverted terminal repeats (ITRs) present at each end of the transposon. See, e.g., D. L. Hartl, A. R. Lohe, E. R. Lozovskaya, *Annu. Rev. Genet.* 31, 337 (1997); R. H. Plasterk, Z. Izsvak, Z. Ivics, *Trends Genet.* 15, 326 (1999). The *Mos1* transposase is the only protein necessary for transposition *in vitro*. L. R. Tosi, S. M. Beverley, *Nucleic Acids Res.* 28,
30 784 (2000). Because no additional factors are required for transposition, the *Mos1* transposon should be capable of transposition in heterologous species, and indeed the

transposon has been mobilized in species evolutionarily distant from *Drosophila*. F. J. Gueiros-Filho, S. M. Beverley, *Science* 276, 1716 (1997); J. M. Fadool, D. L. Hartl, J. E. Dowling, *Proc. Natl. Acad. Sci. U S A* 95, 5182 (1998); A. Sherman, et al., *Nat. Biotechnol.* 16, 1050 (1998); C. J. Coates, N. Jasinskiene, L. Miyashiro, A. A. James, *Proc. Natl. Acad. Sci. U S A* 95, 3748 (1998).

5 In other embodiments, the transposase gene comprises restriction sites 5' of the start codon, restriction sites 5' of the stop codon, and an artificial intron in the transposase gene open reading frame. Other preferred embodiments involve a regulable expression control element which comprises an inducible promoter such as a heat-shock promoter or a tetracycline-regulated promoter. Yet other preferred embodiments comprise the removal
10 of substantially all bacterial plasmid DNA sequences and repeated sequences from the transgene construct. In certain preferred embodiments, the method of the present invention comprises the addition of the 3' untranslated region (UTR) of the *glh-2* gene, which is expressed in the *C. elegans* germline, to the 3' end of the transgene. In such embodiments, the regulable expression control element may comprise a promoter, such as
15 a *glh-2* promoter, a *myo-3* promoter or a heat-shock promoter, which may be used to drive expression of the transgene.

 In yet other embodiments, the method of the present invention includes engineering the transposon to carry a heterologous DNA sequence into a *C. elegans* chromosome. Certain embodiments of the method of the current invention may comprise
20 the steps of introducing a transposon into the *C. elegans*, wherein the transposon comprises the heterologous DNA sequence; introducing a transgene construct into the *C. elegans*, wherein the construct comprises a transposase gene which is operably linked to a promoter and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline; and expressing the transposase, such that the transposon integrates as a single
25 copy into a *C. elegans* chromosome.

 In some embodiments, the transposon may be modified to contain bacterial plasmid DNA sequences. Such sequences may simplify cloning of mutated genes into bacteria from *C. elegans* genomic DNA preparations. In yet other embodiments, the transposon may carry a gene useful for selection or screening purposes.

30 In certain preferred embodiments, FRT/FLP or CRE/LOX recombination sites could be inserted into the transposon. One of skill in the art would appreciate that an

engineered transposon carrying such recombination sites would facilitate insertion of single copy DNA into the *C. elegans* genome. In other embodiments, the transposon could include polyadenylation sites or transcriptional terminators.

In yet other preferred embodiments, the promoter is inducible. In such embodiments, inducible promoters such as a heat-shock promoter, may be used. Yet other preferred embodiments comprise the removal of substantially all bacterial plasmid DNA sequences and repeated sequences from the transgene construct. In certain preferred embodiments, the method of the present invention comprises the addition of the 3' untranslated region (UTR) of the *glh-2* gene, which is expressed in the *C. elegans* germline, to the 3' end of the transgene. In such embodiments, the regulable expression control element may comprise a promoter, such as a *glh-2* promoter, a *myo-3* promoter or a heat-shock promoter, which may be used to drive expression of the transgene.

6. EXAMPLES

The following examples are given to illustrate several embodiments which have been made within the scope of the present invention. It is to be understood that these examples are neither comprehensive nor exhaustive of the many types of embodiments which can be prepared in accordance with the present invention.

Example 1 - Mobilization of Endogenous Tc3 Transposons

About 15 copies of the Tc3 transposon are present in the genome of the wild-type *C. elegans* N2 strain. These transposable elements are inactive in wild-type animals. Our goal is to cause specific mobilization of the endogenous Tc3 copies by expressing the TC3A transposase in the germline. New Tc3 insertions will be used as tags to clone the genes which they have disrupted.

1- TC3A expressed under the *ced-9* promoter causes somatic and germline hops:

The TC3A transposase gene has been cloned behind a *ced-9* promoter. This construct has been coinjected with linearized *C. elegans* genomic DNA and the *lin-15(+)* plasmid into a *lin-15(-)* strain and unstable transgenic strains have been obtained. Transposase activity was assayed by testing whether the construct could excise a Tc3 element from the *unc-22* gene and restore the function of the locus. The *ced-9::Tc3A* arrays have been crossed into *unc-22(r750::Tc3)*; *lin-15(n765ts)* background. Wild-type revertants have been recovered from Unc-22 F1 animals, suggesting functional expression

of the TC3A transposase. One of these extrachromosomal arrays was integrated into a chromosomal location to generate the insertion *oxIs17[ced-9::Tc3A; lin-15(+)]*.

oxIs17 was mapped on the X chromosome and functionally characterized. *lin-15(n765ts); oxIs17[ced-9::Tc3A; lin-15(+)]* males were crossed to *unc-22(r750::Tc3)*; *lin-15(n765ts)* hermaphrodites. Heterozygous nonUnc nonLin hermaphrodites were
 5 cloned and allowed to self-fertilize. It was expected that among the progeny of these animals, there would be found 1/4 Unc animals homozygous for *unc-22(r750::Tc3)*. Of those Unc individuals, 3/4 should be either homozygous or heterozygous for *oxIs17* i.e. nonLin. It was observed, however, that the Unc nonLin animals were greatly under-represented—instead, there were many more nonUnc individuals. Since the *ced-9* gene is
 10 ubiquitously expressed, it was reasoned that TC3A could be present not only in the germline but also in somatic cells and could cause somatic reversion of the Unc phenotype. To test this hypothesis, nonUnc nonLin individuals were cloned, assuming that a fraction of them could be homozygous for *unc-22(r750::Tc3)* despite their wild-type phenotype. Self-progeny of these animals were scored. Individuals heterozygous for
 15 *oxIs17* segregated 1/4 Lin animals (which no longer expressed the TC3A transposase). In this category, plates were identified in which 100 % of the Lin worms were Unc while almost 100% of the nonLin were nonUnc. Hence, the parent hermaphrodite must have been homozygous *unc-22(r750::Tc3)* mutant although its phenotype was wild-type. These data demonstrate that *ced-9::Tc3A* causes somatic reversion of the *unc-22(r750::Tc3)* locus at high frequency.
 20

Rare nonUnc Lin were looked for among the Lin animals generated by self-fertilization of *unc-22(r750::Tc3); lin-15(-); oxIs17/+* hermaphrodites to determine germline reversion rates. Since the Lin worms had lost *oxIs17* and had no TC3A transposase expressed somatically during development, the only way to revert the Unc
 25 phenotype was to receive one reverted copy of the *unc-22* locus. This reversion event had to occur during germline development. Rare nonUnc Lin progeny were identified among Unc Lin progeny (experiment #1: 1 nonUnc Lin in 61 Lin total; exp. #2: 2/106; exp. #3: 4/203). It was concluded that *ced-9::Tc3A* causes an approximately 2% reversion rate of the *unc-22(r750::Tc3)* locus in the germline.

30 2- Expression of TC3A using a *glh-2* promoter:

Since the somatic reversion caused by *ced-9::Tc3A* causes a discrepancy between

the phenotype and the genotype of an individual carrying a locus disrupted by a Tc3 insertion, a TC3A expression vector was designed based on the germline specific *glh-2* gene (gift of Karen Bennett). A plasmid containing a *glh-2* genomic fragment is able to rescue the Glh-2 mutant phenotype and is therefore likely to be expressed in the germline. The *glh-2* open reading frame was deleted and replaced by a multiple cloning site to
 5 generate an expression cassette that retains *glh-2* promoter and 3' untranslated regions. *Tc3A* was inserted to generate *glh-2::Tc3A*. This construct has been coinjected with linearized *C. elegans* genomic DNA and the *lin-15(+)* plasmid into a *lin-15(-)* strain and several unstable transgenic strains have been obtained. A plasmid driving strong expression of the Green Fluorescent Protein (hereinafter "GFP") in the coelomocytes (gift
 10 of Piali Sengupta) has been incorporated also in this array. This allows monitoring of the presence of the array in a *lin-15(+)* background based on GFP expression.

As described above, these arrays have been crossed into *unc-22(r750::Tc3)*; *lin-15(n765ts)* background. In contrast to the *ced-9::Tc3A* experiments, no somatic reversion events were observed. Germline reversion events were observed in the progeny
 15 of *unc-22; oxEx[glh-2::Tc3A]* hermaphrodites (experiment #1: 2/1914 total scored animals; experiment #2: 5/4312). It was concluded that *glh-2::Tc3A* causes a 0.1% reversion rate of the *unc-22(r750::Tc3)* locus in the germline.

Example 2 - Expression of the Mariner Transposase in *C. elegans*

A mutagenesis strategy was also developed that uses the mariner transposon from
 20 the hornfly (gift of David Lampe and Hugh Robertson). Mariner transposons from *Drosophila* are related to *C. elegans* Tc transposons. In fact, members of the Tc/*mariner* family of transposable elements have been identified in a broad range of species. R. H. A. Plasterk & H. G. A. M. van Luenen, *Transposons*, in *C. elegans II* 97-116 (D.L. Riddle et al. eds., 1997). Horizontal transfer may be responsible for the broad distribution of this
 25 family of transposable elements. Horizontal transfer implies that specific host factors are not required for transposition and biochemical characterization has borne this supposition out. Purified transposase is able to catalyze the transposition of mariner or of Tc elements from a host plasmid to a target plasmid. D. J. Lampe et al., *EMBO J* 15:5470-5479 (1996); J. C. Vos et al., *Genes Dev* 10:755-761 (1996). This has enabled researchers to
 30 mobilize mariner elements from *Drosophila* in other Dipteran species. T. G. Loukeris et al., *Proc Natl Acad Sci USA* 92:9485-9489 (1995); T. G. Loukeris et al., *Science*

270:2002-2005 (1995); A. R. Lohe & D. L. Hartl, *Genetics* **143**:365-374 (1996).

Recently, a mariner element from *Drosophila* has been mobilized in *Leishmania*, which represents a trans-kingdom transposition. F. J. Gueiros-Filho & S. M. Beverly, *Science* **276**:1716-1719 (1997). Thus, it was possible that mariner would be active in *C. elegans* as well.

5 A plasmid encoding the mariner transposase HIMAR1 was received from David Lampe and Hugh Robertson. First, the transposase coding sequence was engineered to allow for efficient expression in *C. elegans*. Restriction sites were inserted immediately upstream to the start codon and just before the stop codon to facilitate subcloning of the fragment in various expression vectors. An artificial intron was inserted in the open
10 reading frame since the presence of introns improves the expression level of transgenes in *C. elegans*.

 Engineered *Himar1* was placed under the control of the muscle specific promoter *myo-3*. The *myo-3::Himar1* construct was injected with the *lin-15(+)* plasmid into a *lin-15(-)* strain and unstable transgenic strains obtained. Expression of the HIMAR1
15 transposase was examined first by Western Blot. Extracts were prepared from *oxEx[myo-3::Himar1; lin-15(+)]* worms, run on a denaturing acrylamide gel and transferred to a nitrocellulose membrane. The membrane was probed with previously characterized antibodies that recognize the HIMAR1 protein (provided by David Lampe and Hugh Robertson). In extracts of transgenic worms, an approximately 42 kD protein which
20 corresponds to the expected molecular weight of HIMAR1 was detected. The signal was absent from non-transgenic worm extracts. Using the same antibodies, the protein was visualized in situ using immunofluorescence on *oxEx[myo-3::Himar1; lin-15(+)]* worms. Intense immunoreactivity was detected which was restricted to the nuclei of muscle cells. These data indicate that the HIMAR1 mariner transposase is expressed and properly
25 targeted to nuclei in *C. elegans* cells.

Example 3 - Germline Expression of the Transposase Using the *glh-2* Promoter

 Generation of heritable *Mos1* insertions would require expression of the *Mos* transposase in the germline. However, expression of transgenes in the germline of *C. elegans* is not possible using standard techniques. Typically, transgenic worms are
30 generated by injecting plasmid DNA into the gonads of *C. elegans* (C. C. Mello, J. M. Kramer, D. Stinchcomb, V. Ambros, *Embo J.* **10**, 3959 (1991)). These fragments then

form a simple array of repeated DNA segments. Although gene expression is robust in somatic tissues, such simple arrays are not expressed in the germline or are silenced after a few generations. Co-injection of genomic DNA with plasmid DNA improves germline expression, presumably by preventing tandem repeats in the array. W. G. Kelly, S. Xu, M. K. Montgomery, A. Fire, *Genetics* **146**, 227 (1997). To express the *Mos* transposase in the germline, an expression vector containing the promoter and the 3' UTR of the *glh-2* gene was built. This gene encodes a germline helicase which is specifically expressed in the gonad. M. E. Gruidl, et al., *Proc. Natl. Acad. Sci. U S A* **93**, 13837 (1996). Transgenic lines carrying extrachromosomal arrays of the *glh-2::Mos transposase* construct were generated by microinjection. To maximize expression in the germline, constructs were isolated from plasmid vector sequences and were coinjected with fragmented genomic DNA. (The *Mos* transposase coding sequence was introduced between the promoter and the 3' UTR of *glh-2*. Specifically, this construct (pJL9) contains 2.2 kb of the *glh-2* genomic sequence immediately upstream of the translation start site (nt 29,882 to 32,095 in cosmid C55B7), an Mlu I-Nhe I cloning site, and 0.8 kb of sequence immediately downstream of the *glh-2* stop codon. An Mlu I-Nhe I fragment containing the *Mos* transposase was subcloned into pJL9 to generate the *glh-2::MosTransposase* construct. *lin-15(n765)* hermaphrodites were injected with a Spe I - Kpn I fragment of *glh-2::MosTransposase* (injection concentration 10 ng/ μ l), with *lin-15(+)* (EKL15) and *ofn-1::gfp* (pPD97/98) fragments and N2 worm genomic DNA as described above for the generation of the *oxEx166[hsp::MosTransposase]* array.)

Transposase expression in the germline was determined by assaying for excision of transposons from a defined chromosomal location. Specifically, the *Mos1*-containing extrachromosomal array was integrated into chromosome V to generate *oxIs25[Mos1;rol-6(sd)]*. The *oxIs25* array was mapped less than 0.54 map units from *dpy-11*. Heterozygous *oxIs12/dpy-11* worms were generated. These animals largely segregated Dpy and Rol progeny as expected for these closely linked markers (Figure 6). However, when the *glh-2::Mos Transposase* transgene was crossed in, approximately 16% of the nonDpy progeny were nonRol (15.7 % \pm 0.9, mean \pm SEM, n=44 plates). The nonRol phenotype was stably inherited. It was hypothesized that in those worms, the *Mos* transposase excised *Mos 1* from the integrated array. The resulting DNA breaks were responsible for catastrophic excision of the entire locus, including interspersed *rol-6*

copies. The correlated loss of *rol-6(sd)* and *Mos 1* was confirmed by PCR, in which NonRol individuals were cloned, selfed and DNA was purified from the progeny. *Mos1* containing fragments were detected by PCR using one primer complementary to *Mos1* (oJL102: 5'- CAACCTTGACTGTCTGAACCAACCATAG (SEQ ID NO: 1)) and one primer complementary to *D. mauritiana* flanking DNA (oJL104: 5'-

5 ACAAAGAGCGAACGCAGACGAGT (SEQ ID NO: 2)). Of 188 nonRol worms, only one individual retained a copy of the *Mos 1* fragment that was initially present in the transgene. Based on the phenotypic reversion of the Rol phenotype, it was calculated that 1 in 5 chromosomes experienced catastrophic excision of the transgene ($20.9 \% \pm 1.1 \%$, mean \pm SEM, n=44 plates) The probability p of a single chromosome containing the array

10 of *Mos1* elements transgene experiencing "catastrophic excision" can be derived from a Punnett square where the ratio R of nonRol worms over the total number of the progeny: $R = 1/4p + 1/4p + (1/2p)^2$. These results demonstrated that the *glh-2*-based expression vector expressed the transposase in the germline and that the *Mos 1* transposon in the chromosome was recognized as a substrate.

15 To determine if excision of *Mos 1* from the array was associated with insertion in the genome, the progeny of animals expressing the transposase in the germline were screened for de novo insertions. Specifically, using PCR, the presence of the *Mos 1* element in the absence of the *Drosophila* sequences which flank the transposon in the array was assayed. *Mos1* presence was assessed by PCR using two primers located in the

20 transposon (oJL102 (SEQ ID NO: 1) and oJL103: 5'- TCTGCGAGTTGTTTTGCGTTTGAG (SEQ ID NO: 3)). The absence of *D. mauritiana* flanking sequence was checked using oJL102 (SEQ ID NO: 1) and oJL104 (SEQ ID NO: 2) as described above. In addition, a PCR positive control was performed on each DNA sample using oligonucleotides located in the *cha-1* gene. Because the

25 integrated array containing unmobilized transposons also contained *rol-6(sd)*, insertions were sought in nonRol progeny; specifically, either nonRol animals that experienced catastrophic excision of the array or Dpy progeny (Figure 6B) were analyzed. Insertions were identified in 1% of nonRol progeny (2/227) and in 10 % of Dpy progeny (11/116 F1+F2 Dpys). These results demonstrated that transposition of *Mos 1* could be achieved

30 in the *C. elegans* germline. However, it was observed that high rates of excision were not accompanied by high rates of insertion; these results support previous data indicating that

these two processes are not coupled. H. G. van Luenen, S. D. Colloms, R. H. Plasterk, *Cell* 79, 293 (1994).

Using integrated arrays as a source of transposons prevents the easy recovery of new insertions that occur on the same chromosome; this bias could be circumvented by using an extrachromosomal array of transposons. In addition, extrachromosomal arrays are not completely stable in meiosis, which makes the isolation of strains lacking unmobilized transposons easy after mobilization. Therefore, it was tested whether *Mos 1* could be mobilized from an extrachromosomal array into the chromosomes. Specifically, the *glh-2::Mos Transposase* construct was used to mobilize transposons from a *Mos 1*-bearing array (*oxEx164[Mos1; rol-6(sd)]*). The nonRol progeny from double transgenic animals (*oxEx167[glh-2::MosTransposase]; oxEx164[Mos1; rol-6(sd)]*) were analyzed for transposition events using PCR. An insertion frequency of 1% (3 insertions/ 302 progeny, Table 1) was detected. Thus, these results closely match those obtained for integrated arrays.

Table 1. Frequencies of *Mos1* genomic insertions from an extrachromosomal array. nonRol progeny of *oxEx164[Mos1; rol-6(sd)]; oxEx[MosTransposase]* were analyzed by PCR for the presence of *Mos1* and the loss of the *Drosophila* flanking sequences present in the donor plasmid. *Mos1* presence was assessed by PCR using two primers located in the transposon (*oJL102* (SEQ ID NO: 1) and *oJL103*: 5'-TCTGCGAGTTGTTTTGCGTTTGAG (SEQ ID NO: 3)). The absence of *D. mauritiana* flanking sequence was checked using *oJL102* (SEQ ID NO: 1) and *oJL104* (SEQ ID NO: 2) as described above. In addition, a PCR positive control was performed on each DNA sample using oligonucleotides located in the *cha-1* gene. When heat-shocked (1 hour at 35°C) P0s were moved to fresh plates and eggs were collected for the next 24 hours. *During experiment #5 the stability of the *oxEx164[Mos1; rol-6(sd)]* transgene reached 75 % while in previous experiments it was approximately 20 %.

Transposase construct	Transposition frequency			
	no heat-shock		with heat-shock	
<i>glh-2::MosTransposase</i>	exp #1: 2/108	1.9 %	exp #1: ND	
	exp #2: 0/104	0 %	exp #2: ND	
	exp #3: 1/90	1.1%	exp #3: 0/65	0 %

<i>hsp::MosTransposase</i>	exp #1: ND	exp #1: 4/65	6.2 %
	exp #2: 0/33	exp #2: 3/98	3.1 %
	exp #3: 0/39	exp #3: 6/87	6.8 %
	exp #4: ND	exp #4: 5/85	5.9 %
	exp #5: 0/44*	exp #5: 15/34*	44.1 %

Example 4 - *Mos 1* - Mobilization in the Germline Using a Heat-Shock Promoter

The *glh-2* promoter expresses the transposase in the germline constitutively. Constitutive expression of the transposase has two disadvantages. First, crosses must be set up fresh every generation to guarantee that the array remains intact and does not accumulate inherited changes. Second, because the transposase was expressed in the germline early in development, events identified in the progeny might not be independent but might have occurred when the germline was still comprised of only few cells. Expression limited to adults can be achieved by using a heat-shock promoter. Expression of the transposase could be induced after a strain containing the transposase and transposons had been propagated and expanded to many animals. In addition, heat-shocking animals with mature germlines would maximize the independence of insertion events. Animals expressing the transposase under the control of the heatshock promoter and bearing the integrated transposon (*oxIs25/dpy-11*; *oxEx166[hsp::Mos Transposase]*) were heat-shocked. P0s could only be heat-shocked for 45 minutes; such animals were almost paralyzed, stopped eating and had low brood sizes. Longer heatshock caused the animals to die. It was speculated that this lethality is due to high rates of transposition in somatic cells. Ubiquitous expression of the transposase would cause double strand breaks in the chromosome at the site of integration in every cell which may cause cell cycle arrest or apoptosis. G. Evan, T. Littlewood, *Science* 281, 1317 (1998).

F1 progeny were analyzed for catastrophic excision, that is, for the appearance of nonRol nonDpy progeny (Figure 6A). In contrast with results obtained using the *glh-2* expression vector, catastrophic excision was not observed. Only rare nonRol progeny were generated which were likely to be the result of recombination between the array and the *dpy* marker (Figure 6B). However, by analyzing the Dpy progeny of heat-shocked animals, it was discovered that the heatshock construct caused the efficient insertion of *Mos* into new locations in the genome. Approximately 27% (25/94) of F1 or F2 Dpy worms carried novel transposon insertions (Figure 6B). In addition to novel insertions,

recombinant chromosomes containing both the dpy marker and the original array arose at high frequency. These were identified as Dpy animals containing transposons flanked by *Drosophila* DNA. This hotspot for recombination is likely to arise as a result of double strand breaks introduced into the array by the transposase. A. R. Lohe, C. Timmons, I. Beerman, E. R. Lozovskaya, D. L. Hartl, *Genetics* 154, 647 (2000).

5 It was then tested whether transposition could occur from an extrachromosomal array using the heatshock promoter construct to express the transposase (oxEx166; oxEx164[Mos1; rol-6(sd)]). Hermaphrodites bearing both arrays were heat-shocked as young adults. The nonRol progeny were analyzed by PCR for transposition events. New
10 insertions were observed in 8.9% of the F1 (33/369 progeny, Table 1). Since transposition could have occurred into the transposase containing array, F2 animals that lost this array were isolated from eight transposon-bearing strains. Genomic DNA was prepared from these strains and analyzed for the presence of *Mos1*. The transposon was still detected in all 8 strains, thus demonstrating that the transposon had not inserted in the array. No
15 insertions could be detected in 116 F1 clones derived from non-heat-shocked parents. The frequency of transposition was low but one of the main limiting factors is the stability of the extrachromosomal array that is used as a transposon source. The initial experiments were performed when the array was only 20% stable and transposition frequencies were in the range of 5%; when the array matured and was about 75 % stable, transposition frequency reached 44%. Generating more stable extrachromosomal arrays could increase
20 the frequencies of transposition.

 The heatshock promoter was able to drive expression of *Mos* transposase in the germline and to promote transposition events at a higher rate than obtained using the *glh-2* construct. Temperature has been shown to affect transposition frequency in other organisms. D. Garza, M. Medhora, A. Koga, D. L. Hartl, *Genetics* 128, 303 (1991). One
25 possible explanation for the efficient transposition observed after heatshock is that chromatin structure is somehow altered by the heatshock. Therefore, it was tested whether heatshock itself could account for the difference in transposition frequencies. Parents with extrachromosomal arrays carrying the *glh-2*-transposase construct and carrying the transposon were heatshocked and progeny were tested for transposition. The frequency of
30 transposition was not improved by the heatshock treatment (Table 1). Thus, heatshock itself does not facilitate efficient transposition.

Example 5 - Transposition in Somatic Cells

To determine whether the *Mos1* element could be mobilized in *C. elegans* cells, *Mos1* transposition in somatic cells was first analyzed. The gene encoding the *Mos1* transposase was engineered to improve expression in the worm and placed under the control of a heat-shock promoter. The *Mos* transposase encoding sequence was PCR amplified out of pBluescribe M13+/*Mos1* (M. Medhora, K. Maruyama, D. L. Hartl, *Genetics* 128, 311 (1991), modified as described in Figure 5A and subcloned as a Mlu I-Nhe I fragment between the *hsp-16-48* promoter (H. G. van Luenen, S. D. Colloms, R. H. Plasterk, *Embo J.* 12, 2513 (1993)); E. P. Candido, et al., *Genome* 31, 690 (1989) and the *glh-2* 3' untranslated region (fragment 35383 to 36190 in cosmid C55B7) (M. E. Gruidl, et al., *Proc. Natl. Acad. Sci. U S A* 93, 13837 (1996) (Figure 5A). The resulting construct was used to generate the extrachromosomal array *oxEx166[hsp::MosTransposase]*. (*lin-15(n765)* hermaphrodites were injected in the syncytial gonad with a mixture of the following gel-purified fragments: a Hind III-Eco RI fragment of *hsp::Mos Transposase* (injection concentration: 10 ng/ μ l), a Pst I-Bsi WI fragment of the *ofm-1::gfp* construct (pPD97/98) that expresses GFP in the coelomocytes (gift of Piali Sengupta) (injection concentration: 5 ng/ μ l) and a Kpn I-Eag I fragment of EKL15(*lin-15*+) (S. G. Clark, X. Lu, H. R. Horvitz, *Genetics* 137, 987 (1994)) (injection concentration: 10 ng/ μ l). Plasmid backbones were removed from all purified fragments. Eco RV-digested N2 worm genomic DNA was coinjected at a concentration of 70 ng/ μ l. Another extrachromosomal array, *oxEx164[Mos1; rol-6(sd)]*, contained the *Mos1* transposon. (*lin-15(n765)* hermaphrodites were injected with a 2.2 kb Xho I-Hind III fragment of pBluescribe M13+/*Mos1* that contains the 1.3 kb *Mos1* element flanked by *D. simulans* sequences (M. Medhora, K. Maruyama, D. L. Hartl, *Genetics* 128, 311 (1991) (injection concentration: 10 ng/ μ l) and a 2.2 kb *rol-6(sd)* fragment of pRF4 (J. M. Kramer, R. P. French, E. C. Park, J. J. Johnson, *Mol. Cell. Biol.* 10, 2081 (1990) (injection concentration: 10 ng/ μ l). Eco RV-digested N2 worm genomic DNA was coinjected at a concentration of 80 ng/ μ l to increase the complexity of the array; this array also contained the dominant genetic marker *rol-6(sd)* which causes animals to roll instead of swimming in a sinusoidal fashion. These two strains were crossed and progeny carrying both arrays were heat-shocked as young adults. After 12 hours, the heat-shocked animals were harvested and genomic DNA was prepared. *Mos1* transposition was detected using the strategy

developed by van Luenen *et al.* See H. G. van Luenen, S. D. Colloms, R. H. Plasterk, *Embo J.* 12, 2513 (1993). Specifically, insertions were identified by PCR amplification using one set of primers complementary to the transposon and another set complementary to an arbitrary target gene. DNA purification and PCR were performed as described in H. G. van Luenen, S. D. Colloms, R. H. Plasterk, *Embo J.* 12, 2513 (1993). The primers in *Mos1* were oJL88 (5'-CGCATGCGGCTTACTCAC (SEQ ID NO: 4)) first PCR; and oJL89 (5'-GGCCCCATCCGATTACACCTA (SEQ ID NO: 5)) second PCR. Primers in *unc-49* were oJL19 (5'-GCGAAACGCATACCAACTGTA (SEQ ID NO: 6)) first PCR; and oJL20 (5'-TTCATGCCGAAAAGCAGGCGT (SEQ ID NO: 7)) second PCR. Primers in *gpa-2* were the same as described in H. G. van Luenen, S. D. Colloms, R. H. Plasterk, *Embo J.* 12, 2513 (1993). PCR products were gel-purified and sequenced using oJL89 (SEQ ID NO: 5) as a primer. A PCR product can be obtained only if a transposon has integrated into the target gene. The method is sensitive enough to detect a single insertion in the target gene in a single somatic cell of an adult animal. Insertions in two genes were assayed: the *gpa-2* gene which encodes a G protein subunit (R. R. Zwaal, J. E. Mendel, P. W. Sternberg, R. H. Plasterk, *Genetics* 145, 715 (1997)), and the *unc-49* gene which encodes a GABA receptor. B. A. Bamber, A. A. Beg, R. E. Twyman, E. M. Jorgensen, *J. Neurosci.* 19, 5348 (1999). *Mos1* insertions were detected in both genes (2.5 \pm 1.0 inserts in 10 ng of genomic DNA, mean \pm S.D., n=5 experiments). Given that the maximal distance of the inserts from our gene primers was approximately 1kb, it was estimated that an average of 10 insertions occurred per cell in heat-shocked animals. Insertions were also detected at low frequency in worms that contained the transposon array but lacked the transposase expression construct (0.09 insertions in 10 ng DNA, n=2 experiments). These data indicated that low levels of *Mos1* transposase were expressed from the intact *Mos1* transposons in the extrachromosomal array.

To demonstrate that these transposon insertions represented *bona fide* transposition events, PCR products were gel-purified and the sequence of the insertion sites from the somatic transposition assays was determined. In all cases, the *Mos1* inverted terminal repeats were complete, the *Drosophila* sequences that flanked *Mos1* in the donor plasmid were no longer present, and the insertions all took place at a TA dinucleotide. Transposon insertions were distributed uniformly in exons, introns and 3' noncoding sequences of *gpa-2* and *unc-49* (Figure 5B). Comparison of 22 insertion sites

did not reveal a strong consensus site apart from a bias toward a T at position +1 with respect to the TA dinucleotide (Figure 5C). These data demonstrated that *Mos1* can hop into *C. elegans* chromosomes and that the transposase was sufficient to catalyze insertion without *Drosophila* host factors.

Example 6 - Introduction of Mariner Transposon Copies into the *C. elegans* Genome

5 The full-length copy of the hornfly mariner transposon *Autmar* was gel-purified to remove non-nematode plasmid sequences. Purified *Autmar* was injected with linearized *C. elegans* genomic DNA and the *rol-6(dm)* plasmid into *lin-15(n765ts)* worms and unstable transgenic strains were recovered. Due to the presence of *rol-6(dm)* in the array, transgenic animals roll instead of displaying normal sinusoidal locomotory movements.
10 These animals are Lin when grown at the nonpermissive temperature because they are genotypically *lin-15(-)*. This array was integrated into a chromosomal location to generate the *oxIs21* insertion. *oxIs21* was mapped to chromosome X, 2.5 m.u. away from the *lon-2* locus.

Example 7 -The Mariner Transposase Can Excise Mariner Transposons from *C.*

***Elegans* Chromosomes in the Germline**

15 Engineered *Himar1* was inserted in the *glh-2* germline expression cassette described above. The *glh-2::Himar1* construct was co-injected with linearized *C. elegans* genomic DNA and the *lin-15(+)* plasmid into *lin-15(n765ts)* worms. The *oxEx115* extrachromosomal array is transmitted at each generation to a large fraction of the
20 progeny.

lin-15(n765ts); oxEx119[glh-2::Himar1;lin-15(+)] males were crossed into *lin-15(n765ts) oxIs21[Autmar; rol-6(sd)]* hermaphrodites. As predicted, animals of the cross-progeny were Rol nonLin. At the next generation, it was expected that 1/3 of the Rol animals would be found to be homozygous for *oxIs21*. However, among 48 Rol
25 nonLin cloned individuals, none segregated more than approximately 75% Rols, while 6 of 15 Rol Lin hermaphrodites segregated 100% Rol progeny. After careful characterization of the progeny of parent animals exhibiting various phenotypes, it was concluded that *oxEx115* could elicit the reversion of the Rol phenotype. Presumably, the reversion is caused by excision of the *Autmar* transposons from the integrated array which
30 in turn leads to loss of the adjacent *rol-6(dm)* genes by imprecise repair of the locus. It was concluded that the mariner transposase can excise mariner transposons from *C.*

elegans chromosomes in the germline.

Example 8 - Mobilization of a Heterologous Mariner Transposon in the *C. elegans* Genome

Materials and Methods:

Reagents

5 **Mos1 containing strain:**

The transgenic strain EG1638 that contains *Mos1* has been generated by coinjection of *lin-15(n765)* worms with:

- the 2.2 kB Xho 1-Hind III fragment of pBluescribe M 13+/Mos1, M. Medhora et al., *Genetics* 128:311-318 (1991); (injection concentration: 10 ng/μl)
- 10 - the 2.2 kB Hind III *rol-6* rescuing fragment containing the semi-dominant mutation *rol-6(sul006)*, J. M. Kramer et al., *Mol Cell Biol* 10:2081-2089 (1990); (injection concentration: 10 ng/μl)
- EcoRV digested genomic DNA prepared from N2 worms (injection concentration: 80 ng/μl)

15 The resulting strain *lin-15(ts); oxExl64[Mos1; rol-6(sd)]* exhibits a Rol Muv phenotype when grown above 20°C. The Muv phenotype is not expressed when worms are grown at 15°C.

Mos 1 transposase expressing strain:

20 As shown in Figure 2, the expression vector pJL44 (HSP::MosTase::glh-2) contains the following elements:

- a 377 bp Hspl6-48 heat-shock promoter fragment recovered by PCR from pRP176, H. G. van Luenen et al., *EMBO J* 12:2513-2520 (1993), using the oligos oJL21 5'-CGAAGCTTGCTGGACGGAATAGTGG (SEQ ID NO: 19) and oJL22 5'-CGACGCGTTCTTGAAGTTTAGAGAAT (SEQ ID NO: 20).
- 25 - a 1088 bp fragment containing the *Mos1* transposase coding sequence amplified by PCR from pBluescribe M 13+/Mos1 using oJL77 5'-GCACGCGTTATGTCGAGTTTCGTGCCGAATAAAG (SEQ ID NO: 21) and oJL78 5'-GCGCTAGCTATTCAAAGTATTTGCCGTCGCTCGCGACACATTTTCCCA (SEQ ID NO: 22). An artificial intron (5'-GTAAGTTTAAACATATATACTAACTAACCCATGGATTA-
- 30

TTTAAATTTTCAG-3' (SEQ ID NO: 18) was inserted at position 264 with respect to the ATG.

- a 300 bp fragment containing the *glh-2* 3'UTR (nt 3287 to 4087 with respect to *glh-2* start codon) recovered from a 6.3 kb *glh-2* genomic fragment subcloned in pBluescript KS (Stratagene) (M. E. Gruidl *et al.*, *Proc Natl Acad Sci USA* 93:13837-13842 (1996); gift of Karen Bennett, University of Missouri).

The transgenic strain EG1643 that contains the *Mos1* transposase expression vector has been generated by coinjection of *lin-15(n765)* worms with:

- the Hind III-EcoRI fragment of pJL44 (injection concentration: 10ng/ μ l)
- the Eag I-Kpn I *lin-15* genomic rescuing fragment from EKL15, S. L. McIntire *et al.*, *Nature* 389:870-876 (1997)
- the Pst I-BsiW I fragment of pPD97/98 that drives expression of the Green Fluorescent Protein in the coelomocytes (gift of Piali Sengupta, Brandeis University) (injection concentration: 10 ng/ μ l)
- EcoRV digested genomic DNA prepared from N2 worms (injection concentration: 80 ng/ μ l)

The resulting strain *lin-15(ts); oxExl66[hsp::MosTase::glh-2; pPD97198; lin-15(+)]* has a wild-type phenotype. The presence of the extrachromosomal array causes expression of GFP in the coelomocytes which can be visualized using fluorescence microscopy.

Mobilization of the transposon in the *C. elegans* genome

Mobilization of *Mos1* was achieved by crossing the transposase-expressing strain into worms containing the *Mos1* transposon-containing array. *lin-15(ts); oxExl66[hsp::MosTase::glh-2; pPD97198; lin-15(+)]* hermaphrodites were crossed with N2 males at 25°C. Non-Muv males *lin-15(ts); oxExl66* were crossed with *lin-15(ts); oxExl64[Mos1; rol-6(sd)]* Rol non-Muv hermaphrodites previously grown at 15°C.

The cross was kept at 20°C. Late L4 larvae or young adult Rol worms were transferred to a fresh plate and heat-shocked for 1 hour at 35°C. After 6 hours, non-Muv Rol P0 animals (*lin-15(ts); oxExl64; oxExl66*) were transferred to a fresh plate and allowed to lay eggs for 48 hours. A fraction of the F1 animals contain insertions of *Mos1* in their genome and can be screened for mutant phenotypes.

Identification of transposon insertion sites

Mos1 insertion were identified by inverse PCR, as shown in Figure 3. Genomic DNA was prepared according to standard procedure. Approximately 100 ng of genomic DNA was digested by *Sau3A* in a 10 μ l volume for 3 to 14 hours. The restriction enzyme was inactivated by heating for 20 minutes at 70°C. Fragments were circularized by self-ligation (overnight incubation at 15°C with 5 units of T4 DNA ligase).

3 μ l of ligated DNA was used for PCR amplification. A first round of amplification was performed using the primers oJL103 5'-TCTGCGAGTTGTTTTGCGTTTGAG (SEQ ID NO: 3) and oJL114 5'-AAAGATTCAGAAGGTCGGTAGATGGG (SEQ ID NO: 10) (30 cycles, 45" at 94°C / 1' at 60°C / 1'15" at 72°C, magnesium chloride concentration: 1.5 mM). The product of the first amplification was diluted 100-fold and subjected to a second round of amplification using the nested primers oJL115 5'-GCTCAATTCGCGCCAACTATG (SEQ ID NO: 11) and oJL116 5'-GAACGAGAGGCAGATGGAGAGG (SEQ ID NO: 12) (25 cycles, 45" at 94°C / 1' at 62°C / 1'15" at 72°C, magnesium chloride concentration: 2.5 mM). Resulting fragments were run on an agarose gel, gel-purified and sequenced either directly or after subcloning.

Figure 4 contains the sequence of an inverse PCR product demonstrating insertion of *Mos1* in chromosome X. Nucleotides in capital letters are from the *Mos1* transposon. *C. elegans* flanking genomic region is in lower case. It matches the Y47C4.Contig215 sequence from chromosome X available at the Sanger Centre.

Mos1, a *mariner*-like transposon isolated from *Drosophila mauritiana* was used. Transgenic worms containing *Mos1* in an extrachromosomal array were crossed with transgenic worms containing an expression vector in which a heat-shock promoter (*hsp 16-48*) drives the expression of the *mos* transposase (Figure 1). Cross-progeny containing both the *Mos1* transposon and the *mos* transposase were isolated. Heat-shock of these worms induced the expression of the transposase which in turn caused *Mos1* elements to transpose from the extrachromosomal array into the *C. elegans* genome. Five insertions were isolated, for a rate of one in seventeen animals analyzed. However, this array is only 20% stable per generation. Thus, there in on average one transposition into chromosomes for every three germ cells exposed to the transposon.

Some insertions will disrupt genes and cause mutant phenotypes. Mutant worms

are outcrossed with wild-type worms containing no *Mos1* transposon. Since the insertion responsible for the mutation cosegregates with the mutant phenotype, it is possible to isolate the single relevant *Mos1* insertion after only a few outcrosses. Genomic DNA is then prepared from the outcrossed mutant. Regions flanking the transposon are recovered by inverse PCR and sequenced. Comparison of flanking sequences with the *C. elegans* genome sequence allows immediate identification of the mutated gene. This new mutagenesis system will significantly speed up the identification of genes of interest using *C. elegans* as a genetic model.

Example 9 - *Mos1* Mutagenesis and Rapid Cloning of Genes

In one embodiment, the method described in this invention is capable of generating mutations which can be rapidly cloned based on the *Mos1* unique DNA tag. To demonstrate that this is true, mutants have been identified and the relevant genes have been cloned using inverse PCR. Specifically, a morphological mutant in *C. elegans* was isolated which causes the worms to be short and squat. Such mutations are called dumpy mutations and are given the three letter designation "dpy". A dumpy animal was identified after mobilization of the wild-type *Mos1* transposon. DNA was prepared, cleaved with the restriction enzyme *Sau3A*, and religated. Inverse PCR was performed using primers contained within the transposon but facing outward. The amplified fragment was sequenced. The *Mos1* element was inserted 175 nucleotides 5' of F54D8.1, which encodes a collagen protein. An inspection of the genetic map demonstrated that this insertion is in a chromosomal interval which also contains the *dpy-17* gene which had been previously defined by point mutations using chemical mutagens by Sydney Brenner in 1974. A complementation test was performed and the test demonstrated that this mutation was an allele of *dpy-17*. Thus, the method is capable of rapidly demonstrating the molecular identity of a gene which had remained unknown for almost 30 years. Mutants incapable of detecting high osmotic gradients (Osm) were also screened for. The first Osm mutant identified was cloned in a similar manner and proved to be an insertion of *Mos1* in exon 10 of the *eat-4* gene.

Example 10 - Targets of Transposase and Transposon

For *Mos1* insertions to be useful for the cloning of mutated genes, the transposase must specifically mobilize *Mos1* and not other mariner elements. The *C. elegans* genome contains endogenous transposons. Apart from the most active Tc1 and Tc3 transposons,

which are distantly related to *Mos1*, every haploid genome contains at least 55 copies of a Mariner Like Element (MLE), which is closely related to *Mos1*. M. M. Sedensky, S. J. Hudson, B. Everson, P. G. Morgan, *Nucleic Acids Res.* **22**, 1719 (1994); H. M. Robertson, D. J. Lampe, *Mol. Biol. Evol.* **12**, 850 (1995). Since in a few cases transposases of the Mariner family have been shown to cross-mobilize distinct but related transposons (P. Sundararajan, P. W. Atkinson, D. A. O'Brochta, *Insect Mol. Biol.* **8**, 359 (1999)), it was tested whether *Mos* transposase expression had triggered transposition of the endogenous MLEs. Eight strains in which *Mos1* insertions had occurred were analyzed by Southern blot for changes in MLE distribution. No changes in MLE distribution were detected. Worm genomic DNA of *lin-15(n765)* and *Mos1*-containing strains was extracted, Bgl II digested and run for Southern blot analysis using standard procedures. Oligos oJL132: 5'-ATATGCGGTGCGATGGGTGAG (SEQ ID NO: 8) and oJL133: 5'-GGCGAACGCGATGAGAAGAAAG (SEQ ID NO: 9) were used to amplify a 842 bp MLE fragment from N2 worm genomic DNA. The PCR product was sequenced and used for probe synthesis, (data not shown) indicating that *Mos* transposase is specific for *Mos1* in the *C. elegans* germline.

How many insertions occurred in every animal and what were their distributions? The number of chromosomal insertions per strain was determined by Southern blot analysis in eight insertion strains. Only one insertion per strain was detected (Figure 7A). To determine the location of the mobilized transposons, the left junctions of 17 insertions were cloned using inverse PCR. Approximately 100 ng of total genomic DNA was digested with Sau3A, self-ligated under dilute conditions, and then 3 % of the ligation was subjected to two rounds of nested PCR using the following primers: oJL103 (SEQ ID NO: 3)/oJL114 5'-AAAGATTCAGAAGGTCGGTAGATGGG (SEQ ID NO: 10) (first PCR), oJL115 5'-GCTCAATTCGCGCCAACTATG (SEQ ID NO: 11) / oJL116 5'-GAACGAGAGGCAGATGGAGAGG (SEQ ID NO: 12) (second PCR). PCR products were purified on agarose gel and sequenced using oJL115 (SEQ ID NO: 11) as a primer. In agreement with the Southern blot experiments, only one insertion per strain was detected. Insertion sites were distributed on all six chromosomes (Figure 7B). Transposition occurred into exons, introns and intergenic regions (Table 2). Sequences flanking both sides of the transposon were determined for nine of the localized insertions. In each case, the inverted terminal repeats were complete and flanked by a TA dinucleotide that arose from the duplication of the original TA found in the genomic

sequence (Figure 7C).

Table 2. Properties of *Mos1* genomic insertions. *Mos1* flanking were compared with the *C. elegans* genome sequence. Physical location in the genome is given as the nucleotide position of the corresponding clone in the *C. elegans* database (ACeDB).

5

10

15

20

25

Isolation name	Transposon source	Physical location	Interpolated genetic location	Genefinder predictions
oxTi1	Extrachromosomal	Y65B4BL @27,362	LGI, - 19	Intergenic
oxTi2	Extrachromosomal	Y44E3A @ 34,440	LGI, - 4.75	Intergenic
oxTi3	Extrachromosomal	M01E5 @19,740	LGI, + 29.9	Intergenic
oxTi4	Extrachromosomal	T13C2 @ 4,948	LGII, + 0.1	Exon #4 of F41G.12
oxTi5	Extrachromosomal	K08E5 @ 31,631	LGIII, + 4.61	Intergenic
oxTi6	Extrachromosomal	H23L24 @ 4,529	LGIV, + 3.9	Intergenic
oxTi7	Extrachromosomal	K08D8 @ 4234	LGIV, + 6.6	Intergenic
oxTi8	Extrachromosomal	R09B5 @ 22,929	LGV, -19.0	Exon #6 of R09B5.12
oxTi9	Extrachromosomal	Y69H2 @ 39,771	LGV, + 17.49	Intron #5 of Y69H2.4
oxTi10	Extrachromosomal	Y47C4A	LGX, - 20	Repeat
oxTi11	Extrachromosomal	C34E11 @ 12,022	LGX, + 6.55	Exon #10 of C34E11.1
oxTi12	Integrated array	Y71A12B @ 50,370	LGI, + 21	Intergenic
oxTi13	Integrated array	Y48G1C @ 19,916	LGI, - 19.8	Intergenic
oxTi14	Integrated array	C17F4 @ 22,793	LGII, - 8.06	Exon #18 of <i>gcv-19</i>
oxTi15	Integrated array	F35C5 @ 5,735	LGII, + 10	Intergenic
oxTi16	Integrated array	C06B3 @ 14,747	LGV, + 5.79	Intergenic
oxTi17	Integrated array	R01H2 @ 20,193	LGIII, - 0.86	Intergenic

Comparison of the insertion site sequences did not reveal a strong consensus motif for the target DNA. Molecular analysis of the insertions therefore demonstrated that *Mos1* insertion obeyed properties previously observed for mariner class transposons. However, a formal possibility remained that *Mos1* hopped into the genomic DNA present in one of the extrachromosomal arrays and that recombination occurred subsequently between the

array and the genome. To rule out this possibility, the insertion *oxTi4* which was positioned 35 kb away from *snt-1* was genetically mapped. In agreement with this physical location, *oxTi4* was mapped less than 2.5 map units from *snt-1*: 20 *Snt-1* individuals were cloned from the self-progeny of *oxTi4/snt-1* hermaphrodites. None of the mutants segregated *oxTi4*. The presence of *oxTi4* was determined by PCR using one

5 *Mos1* primer pointing towards the right end of the transposon (oJL89 (SEQ ID NO: 5)) and one primer in the genome (oJL129 5'-CCAAATGCGTCTGTCCCACTC (SEQ ID NO: 13)). A PCR positive control was performed on each DNA sample using *cha-1* primers.

Example 11 - Remobilization of a Genomic Transposon Insertion

10 The transposition events documented above were all excisions from an array of transposons residing in *Drosophila* DNA. To determine whether the transposase acts on a single *Mos1* transposon in a *C. elegans* chromosome, the *oxTi4* insert was remobilized. Primers for PCR were designed flanking the *oxTi4* insertion. A first PCR round was performed with primers located 1671 nt upstream and 3144 bp downstream to *oxTi4*

15 (respectively oJL149 5'- AAGTATGGCCAAACGACCCGACAC (SEQ ID NO: 14) and oJL150 5'- GCATTGGCACCTTTCTCCCTTCT (SEQ ID NO: 15)). A second round was performed using primers 493 bp upstream and 913 downstream to *oxTi4* (respectively oJL145 5'- ACAGGCAGCATTGTTGTAGTCT (SEQ ID NO: 16) and oJL148 5'- AGGCTGCCTCGTAAGTTCCTACAG (SEQ ID NO: 17)). Short PCR products were gel

20 purified, subcloned and sequenced. The transposase-expressing transgene (*oxEx167[glh-2:Transposase]*) was crossed into animals homozygous for the *oxTi4* insertion and DNAs from the progeny were analyzed for amplified fragments shorter than the insertion. These shorter PCR products represented a variety of excision events, including the three nucleotide excision footprint previously characterized for *Mos1*

25 excisions (G. Bryan, D. Garza, D. Hartl, *Genetics* 125, 103 (1990)), as well as smaller footprints, excisions and even incomplete excisions (Table 3). Since these products could arise from excision events in somatic cells, progeny animals that lost the transposase expression array were analyzed. Pools of 15 individuals from *oxTi4*;

30 *oxEx167[glh-2:Transposase]* progeny that lost the transposase array were transferred to fresh plates and allowed to lay eggs for 24 hours. Adult worms were then analyzed by a single round of PCR using the primers oJL145 (SEQ ID NO: 16)-oJL148 (SEQ ID NO: 17). Sixty individuals were cloned from the progeny of the pool exhibiting short PCR

product and analyzed at the next generation to identify clones that lost *oxTi4*. One animal was identified among 954 progeny in which excision of the transposon had occurred. In this animal the excision left a 3 bp footprint and the duplicated TA dinucleotide which together resulted in a +2 frameshift. These data indicate that single copies of the *Mos1* *Drosophila* transposon can excise from *C. elegans* DNA in the germline to introduce frameshift or deletion mutations at the transposon insertion site.

Table 3. Lesions generated by excision of the *oxTi4* insert. The extrachromosomal [*glh-2:Transposase*] transgene was crossed into animals homozygous for the *oxTi4* insertion. PCR was used to analyze the *oxTi4* insertion site after the loss of *Mos1*. Pools of 15 individuals from *oxTi4*; *oxEx167*[*glh-2:Transposase*] progeny that lost the transposase array were transferred to fresh plates and allowed to lay eggs for 24 hours. Adult worms were then analyzed by a single round of PCR using the primers oJL145 (SEQ ID NO: 16)-oJL148 (SEQ ID NO: 17). Sixty individuals were cloned from the progeny of the pool exhibiting short PCR product and analyze at the next generation to identify clones that lost *oxTi4*. Top line: sequence of *oxTi4*. Lower case: *Mos1* sequence. Upper case: genomic sequence. Bold: TA dinucleotide duplicated during *Mos1* insertion. Bottom lines: excision products. Dash: deleted base pairs. The insertion (bottom line, italic letters) corresponds to an internal fragment of *Mos1* (nt 147 to 178).

20 CTCTTTTCCAGACGAGTAccaggtgtac.....tacacctgaTATATCCTTTTG TTCCTT

CTCTTTTCCAGACGAGTA-----TATATCCTTTTG TTCCTT

CTCTTTTCCAGACGAGTA-----aTATATCCTTTTG TTCCTT

25 CTCTTTTCCAGACGAGTA-----tgaTATATCCTTTTG TTCCTT

CTCTTTTCCAGACGAGTAc-----TATATCCTTTTG TTCCTT

-----249 bp deletion---tgaTATATCCTTTTG TTCCTT

CTCTTTTCCAGACGAGa-----143 bp deletion-----

CTCTTTTCCAGACGAGTA-----188 bp deletion-----

30 -----463 bp deletion-----

CTCTTTTCCAGACGAGTA attgtttactctcagtcgagtcgaacatgtcgaTATCCTTTTG TTCCTT

Example 12: - Engineering Mutations in the *C. elegans* Genome by Transgene Instructed DNA Double Strand Break Repair Following Mos1 Excision

Germline expression of the *Mos* transposase under the control of the *glh-2* promoter causes reexcision of single copies of *Mos1* inserted in the *C. elegans* genome. Remobilization of the transposon causes a DNA double strand break (DSB) at the site of excision which is repaired by the cellular machinery. In 1992, R. Plasterk and J. Groenen (*EMBO J.* 11:287) demonstrated that a DSB caused by excision of a Tc1 transposon in a *mut-6(st702)* background can be repaired using DNA contained in an extrachromosomal array that carries sequences homologous to the region of excision. As a result, sequences flanking the break can be replaced by sequences contained in the transgene. This strategy provides a way to engineer mutations in the genome. However, this approach never became a routine strategy probably because transposition is not controlled and excision occurs at low rates in such mutant strains.

The controlled transposition of *Mos1* provides an efficient tool to use this strategy for engineering of the *C. elegans* genome: after a *Mos1* insertion has been identified in the gene of interest, a transgene is constructed with mutated sequences homologous to the region of insertion. The transgene that carries the *glh-2::MosTransposase* expression vector is crossed into the strain that contain the *Mos1* genomic insertion and the template transgene. Expression of *Mos* transposase causes *Mos1* excision and the progeny is screened by PCR for transgene instructed repair at the excision site (Figure 8).

The feasibility of regulated mobilization of a heterologous transposon in the *C. elegans* germline was thus demonstrated. The characteristics of *Mos1* transposition suggest that it could be used as a technique for tagging mutant genes. First, the *Mos* transposase does not activate transposition of endogenous transposons. Second, transposition of *Mos* in the germline is strictly dependent on the expression of the transposase. In this respect the use of a heat-shock promoter to express the transposase is of particular interest since it provides a convenient way to turn transposition on and off and to stabilize new inserts. Third, insertion sites of *Mos1* in the genome do not exhibit strong sequence bias. Transposons were inserted into exons, introns and intergenic regions. Comparison of the insertion sites did not reveal a strong consensus sequence apart from the TA dinucleotide. Fourth, excision and insertion frequencies can be differentially manipulated by expressing the transposase under the control of different promoters. The heatshock promoter caused very low rates of excision and loss of the

transposon array but high rates of transposon insertion. The *glh-2* promoter construct caused a low rate of insertion but a high rate of excision and loss of the transposon array. Since transposon insertions frequently do not disrupt gene function in *C. elegans* even if the insertion occurs in an exon (A. M. Rushforth, B. Saari, P. Anderson, *Mol. Cell. Biol.* 13, 902 (1993); A. M. Rushforth, P. Anderson, *Mol. Cell. Biol.* 16, 422 (1996)),

5 transposons are usually remobilized to generate deletion alleles (D. Eide, P. Anderson, *Mol. Cell. Biol.* 8, 737 (1988); R. R. Zwaal, A. Broeks, J. van Meurs, J. T. Groenen, R. H. Plasterk, *Proc. Natl. Acad. Sci. U S A* 90, 7431 (1993)). It was thus demonstrated that the *glh-2* expression construct can be used to generate deletion alleles of the genes containing *Mos1* insertions.

10 *Mos1* transposition in *C. elegans* will allow the development of two new genetic tools. First, mutations identified in forward screens using *Mos1* will allow the rapid cloning of the mutated gene. Second, a library of insertions localized in the genome could be generated; the *glh-2* expression construct could then be used to remobilize these insertions at high frequency and generate deletion and frameshift mutations in genes of
15 interest.

CLAIMS:

1. A method of regulated expression of a heterologous gene in cells of the germline of *C. elegans* comprising the steps of:
 - a. inserting a transgene construct into the *C. elegans*, wherein the construct comprises the heterologous gene operably linked to a promoter and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline, wherein the promoter is an inducible promoter or a germline-specific promoter; and
 - b. expressing the heterologous gene.
2. The method of Claim 1, wherein the promoter is inducible.
3. The method of Claim 2, wherein the promoter comprises a heat-shock promoter.
4. The method of Claim 2, wherein the promoter comprises a tetracycline-regulated promoter.
5. The method of Claim 1, wherein the construct is substantially free of bacterial plasmid sequences.
6. The method of Claim 1, wherein the construct is substantially free of repeated DNA sequences.
7. The method of Claim 1, wherein the 3' untranslated region comprises a *glh-2* 3' untranslated region.
8. The method of Claim 1, wherein the promoter comprises a *glh-2* promoter.
9. A transgene construct for expression in *C. elegans* comprising a heterologous gene operably linked to a promoter and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline, wherein the promoter is an inducible promoter or a germline-specific promoter.
10. The transgene construct of Claim 9, wherein the promoter is inducible.
11. The transgene construct of Claim 10, wherein the promoter comprises a heat-shock promoter.
12. The transgene construct of Claim 10, wherein the promoter comprises a tetracycline-regulated promoter.
13. The transgene construct of Claim 9, wherein the construct is substantially free of bacterial plasmid sequences.
14. The transgene construct of Claim 9, wherein the construct is substantially free of repeated DNA sequences.

15. The transgene construct of Claim 9, wherein the 3' untranslated region comprises a *glh-2* 3' untranslated region.
16. The transgene construct of Claim 15, wherein the promoter comprises a heat-shock promoter.
17. The transgene construct of Claim 9, wherein the promoter comprises a *glh-2* promoter.
18. The transgene construct of Claim 9, wherein the heterologous gene is a transposase.
19. The transgene construct of Claim 9, wherein the heterologous gene is a TC3A transposase gene.
20. A method of transposon-mediated mutagenesis in a *C. elegans* genome, comprising the steps of:
 - a. introducing a transgene construct into the *C. elegans* genome, wherein the construct comprises a transposase gene which is operably linked to a regulable expression control element and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline; and
 - b. expressing the transposase gene, such that a transposon in the *C. elegans* genome transposes, causing a mutation.
21. The method of Claim 20, wherein the transposons comprise endogenous transposons.
22. The method of Claim 21, wherein the transposons comprise Tc3 transposons.
23. The method of Claim 20, wherein the transposase gene is a TC3A transposase gene.
24. The method of Claim 22, wherein the transposase gene is a TC3A transposase gene.
25. The method of Claim 21, wherein the regulable expression control element is an inducible promoter.
26. The method of Claim 26, wherein the promoter comprises a heat-shock promoter.
27. The method of Claim 25, wherein the promoter comprises a tetracycline-regulated promoter.
28. The method of Claim 20, wherein the construct is substantially free of bacterial plasmid DNA sequences.
29. The method of Claim 20, wherein the construct is substantially free of repeated

DNA sequences.

30. The method of Claim 20, wherein the 3' untranslated region comprises a *glh-2* 3' untranslated region.
31. The method of Claim 30, wherein the regulable expression control element
5 comprises a heat-shock promoter.
32. The method of Claim 30, wherein the regulable expression control element comprises a *glh-2* promoter.
33. The method of Claim 20, further comprising introduction of one or more additional copies of an endogenous transposon into the *C. elegans* germline.
- 10 34. The method of Claim 33, wherein the endogenous transposon is a Tc3 transposon.
35. The method of Claim 20, wherein the transposons comprise heterologous transposons.
36. The method of Claim 35, wherein the heterologous transposons are introduced into the *C. elegans* genome.
- 15 37. The method of Claim 35, wherein the transposons comprise *Mos 1* transposons.
38. The method of Claim 35, wherein the transposase gene comprises restriction sites 5' of the start codon, restriction sites 5' of the stop codon, and an artificial intron in the transposase gene open reading frame.
39. The method of Claim 35, wherein the regulable expression control element is an
20 inducible promoter.
40. The method of Claim 39, wherein the promoter comprises a heat-shock promoter.
41. The method of Claim 39, wherein the promoter comprises a tetracycline-regulated promoter.
42. The method of Claim 35, wherein the construct is substantially free of bacterial
25 plasmid DNA sequences.
43. The method of Claim 35, wherein the construct is substantially free of repeated DNA sequences.
44. The method of Claim 35, wherein the 3' untranslated region comprises a *glh-2* 3' untranslated region.
- 30 45. The method of Claim 44, wherein the regulable expression control element comprises a heat-shock promoter.
46. The method of Claim 44, wherein the regulable expression control element

comprises a *glh-2* promoter.

47. A method of introducing a heterologous DNA sequence into a *C. elegans* chromosome comprising the steps of:
- a. introducing a transposon into the *C. elegans*, wherein the transposon comprises the heterologous DNA sequence;
 - b. introducing a transgene construct into the *C. elegans*, wherein the construct comprises a transposase gene which is operably linked to a promoter and a 3' untranslated region of a gene that is expressed in the *C. elegans* germline; and
 - c. expressing the transposase, such that the transposase integrates as a single copy into a *C. elegans* chromosome.
48. The method of Claim 47, wherein the heterologous DNA sequence comprises a bacterial plasmid DNA sequence.
49. The method of Claim 47, wherein the gene carried on the transposon is useful for selection or screening purposes.
50. The method of Claim 47, wherein the transposon contains FRT/FLP recombination sites.
51. The method of Claim 47, wherein the promoter is inducible.
52. The method of Claim 47, wherein the promoter comprises a heat-shock promoter.
53. The method of Claim 47, wherein all bacterial plasmid sequences have been removed from the construct.
54. The method of Claim 47, wherein the construct is substantially free of repeated DNA sequences.
55. The method of Claim 47, wherein the 3' untranslated region comprises a *glh-2* 3' untranslated region.
56. The method of Claim 47, wherein the promoter comprises a *glh-2* promoter.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/40091

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C12N 15/09, 15/70, 15/63, 15/00

US CL : 435/6, 320.1, 455, 473; 800/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 320.1, 455, 473; 800/21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST, medline, EMBASE, SciSearch.**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,051,430 A (PLASTERK, et al.) 18 April 2000 (18.04.2000), columns 1-4.	1-6 and 9-14
X	FUKUSHIGE, T. et al. Modulation of Gene Expression in the Embryonic Digestive Tract of <i>C. elegans</i> . Developmental Biology. 1996, Vol. 178, pages 276-288, especially pages 276 and 277.	1-56
X	VAN LUENEN, H. et al. The Mechanism of Transposition of Tc3 in <i>C. elegans</i> . Cell. 21 October 1994, Vol. 79, pages 293-301, entire document.	1-56
X	VOS, J. et al. Transposase is the Only Nematode Protein Required for in vitro Transposition of Tc1. Genes & Development. 1996, Vol. 10, pages 755-761, especially results.	1-56
Y	PLASTERK, R. Reverse Genetics of <i>Caenorhabditis elegans</i> . BioEssays. September 1992, Vol. 14, No. 9, pages 629-633, entire document.	1-56
X	PLASTERK, R. et al. Targeted Alterations of the <i>Caenorhabditis elegans</i> Genome by Transgene Instructed DNA Double Strand Break Repair Following Tc1 Excision. The EMBO Journal. 1992, Vol. 11, No. 1, pages 287-290, entire document.	1-56
X	GRUIDL, M. et al. Multiple Potential Germ-line Helicases are Components of the Germ-line-specific P Granules of <i>Caenorhabditis elegans</i> . Proc. Natl. Acad. Sci., USA. November, 1996, Vol. 93, pages 13837-13842, entire document.	7,8 and 15-17

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 July 2000 (28.07.2000)

Date of mailing of the international search report

23 AUG 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

David Nikodem

Telephone No. (703) 308-0196